N/A N=10 Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome
Hunter Syndrome
Primary: Levels of Total Glycosaminoglycan (GAG) in CSF — 816.750 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=231 Lumbar Puncture and Syphilis Outcome
Syphilis
Primary: Appropriate Decline in Serum Rapid Plasma Reagin Test (RPR) Titer — 38; 30 Participants — p=0.29
Phase 2 N=10 Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid
Pharmacokinetics
Primary: Unbound Ceftolozane Exposure in the Plasma — 322.6 mg*h/L
N/A N=5 Non-invasive Estimation of CSF Pressure Using MRI in Patients With Spontaneous Intracranial Hypotension
Intracranial Hypotension
Primary: Intracranial Pressure Measurements Estimated by the MRICP Technique. — 6.5 cm H20
N/A N=8 Cerebrospinal Fluid (CSF) Pharmacokinetics of Antimicrobials in Children
Infections
Primary: CSF:Serum Ratio of Vancomycin — 0.08 ratio
N/A N=30 Chronic Insomnia and CSF Markers of Dementia
Insomnia Chronic
Primary: CSF Markers Related to Dementia — 4332.1; 4824.0; 393.2; 419.4 picograms per milliliter
N/A N=162 Posterior Fossa Decompression With or Without Duraplasty for Chiari Type I Malformation With Syringomyelia
Arnold-Chiari Malformation, Type 1 · Chiari Malformation Type I · Type I Arnold-Chiari Malformation
Primary: The Number of Participants With Surgical Complications — 8; 10 Participants
Phase 1 N=14 The Rilpivirine Cerebrospinal-fluid (CSF) Study
HIV
Primary: CSF:Plasma Ratio of Rilpivirine Levels — 1.4 ratio expressed as a percentage
N/A N=46 Neurologic Injuries in Adults With Urea Cycle Disorders
Brain Diseases, Metabolic, Inborn · Urea Cycle Disorder · Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003
N/A N=21 Influence of Yogic Breathwork on CSF Circulation
CSF Circulation
Primary: CSF Flow Velocities — 1.36; 1.31; 1.48; 1.15 cm/s
N/A N=15 Changes in Cerebral Blood Flow in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain
Pain · Low Back Pain · Leg Pain
Primary: Cerebral Blood Flow and VAS With Optimal Paresthesia Coverage Compared With SCS Off
N/A N=33 FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR Extension
Subarachnoid Hemorrhage
Primary: Mean Change in Cisternal Blood From Enrollment to Catheter Removal — -64.7 percent change
N/A N=20 Dispersal Pattern for Spine Injections (Gadolinium Contrast)
Cervical Radiculopathy
Primary: Injection Dispersal Patterns Measured (in cm) in the Superoinferior Directions on Post-injection MRI With a Calibrated Internal Measurement Software. — 14.73 cm
Phase 1 N=25 Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809
Healthy
Primary: Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to 14h (AUC0-14) — 421.0; 829; 1840.0; 3300.0 nanomole*hours/Liter (nmol∙h/L)
N/A N=10 Microembolic Signals and Cerebrospinal Fluid Markers of Neuronal Damage After Surgical Aortic Valve Replacement
Aortic Stenosis
Primary: Transcranial Doppler(TCD) Microembolic Signals During Surgical Aortic Valve Replacement Surgery — 354 units on a scale
N/A N=8 Postural Stability in Cervical Spinal Myelopathy
Cervical Spondylotic Myelopathy
Primary: Virtual Environment TBI System (VETS) Assessment of Static Posturography — 11; 13.0; 48.4; 19.1 Square Centimeters
N/A N=37 Ventriculostomies in SAH: ICP Open or Not?
Subarachnoid Hemorrhage
Primary: Cerebral Artery Vasospasm — 16; 7 Participants
N/A N=47 Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery
Cerebral Palsy · Multiple Sclerosis · Traumatic Brain Injury
Primary: Classification of Catheter Function by CSF Signatures vs. Physician's Standard Trouble-shooting Diagnosis — 13; 16 Subjects whose CSF data agree with MD Dx
N/A N=30 Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
Conversion Disorder
Primary: Gray Matter Volume Biomarkers of 6 Month Prognosis as Measured by Voxel Based Morphometry - Within Group Comparison — 4.18; 3.27; 3.85; 3.76 peak voxel z-score
Phase 2 N=16 A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
Hunter Syndrome
Primary: Number of Serious Adverse Event (SAE) — 0; 8; 3; 3 events
Phase 2 N=42 Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid
Alzheimer's Disease
Primary: Change From Baseline in Aβ1-42 Cerebrospinal Fluid (CSF) Levels. — 75.3; -45.5; -86.2; -283.0 pg/mL
N/A N=14 Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer
Breast Cancer · Leptomeningeal Metastasis
Primary: Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status) — 3; 1 Participants
Phase 3 N=15 Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals
HIV-1-infection
Primary: Total Doravirine Concentrations in Cerebrospinal Fluid — 58.6 ng/ml
N/A N=10 Respiratory Capacity and Swallowing Function in Spinal Disorders: A Pilot Study
Spinal Cord Injuries · Deglutition Disorders
Primary: Number of Participants Displaying Unsafe Swallowing — 0; 0; 0; 0 Participants
Phase 3 N=19 Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury
Spinal Cord Injury
Primary: Systolic Blood Pressure — 116.3; 98.0 mmHg
Phase 1 N=20 Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers
Healthy
Primary: Ratio of Cmax of BI 409306 in CSF Compared to Plasma — 0.267; 0.244; 0.294; 0.335 Ratio — p=1.0000
N/A N=212 Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease
Anemia, Sickle Cell
Primary: Wechsler Adult Intelligence Scale (WAIS)-III Performance IQ — 90.6; 95.9 Points on a scale — p=0.008
N/A N=23 Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Multiple Sclerosis
Primary: Change in the Number of Enhancing Leptomeningeal Foci on 1 Year Follow up Compared to Baseline in MS Patients Treated With Ocrelizumab. — 0.07 number of enhancing foci
Phase 2 N=21 The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury
Spinal Cord Injury · Autonomic Dysreflexia · Baroreceptor Integrity
Primary: Systolic Blood Pressure — 93.21; 107.00; 95.8; 93.84 mmHg
Phase 3 N=57 Treating Brain Swelling in Pediatric Cerebral Malaria
Malaria, Cerebral
Primary: Number of Participants Who Died — 5; 5; 5 Participants